Description

GRAIL’s mission is to detect cancer early. GRAIL is a healthcare company focused on alleviating the global burden of cancer through the development of pioneering technologies that detect and identify multiple deadly cancer types early. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection (MCED), risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. The company combines the power of next-generation sequencing; population-scale clinical studies; and state-of-the-art machine learning, software and automation to work toward changing the trajectory of cancer mortality. GRAIL’s Galleri is a first-of-its-kind MCED test that can detect a shared cancer signal across 50+ types of cancer and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps. The test can help detect cancer in early stages before it has spread and when treatment is more likely to be successful.